Literature DB >> 7026735

The effect of bromocriptine (BCT) on the on-off phenomenon.

R Glantz, C G Goetz, P A Nausieda, W J Weiner, H L Klawans.   

Abstract

Twenty-three patients with idiopathic Parkinson disease with classic "on-off" phenomena were studied prospectively during treatment with bromocriptine (BCT). Patients were evaluated for an average of 6 to 12 months and received an average of 56.5 mg of BCT. Nine patients (39%) showed improvement in terms of "on-off". When evaluated retrospectively, it appeared that the only difference between the responders and non-responders was a younger mean age (57.1 to 63.2).

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7026735     DOI： 10.1007/bf01253095

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  10 in total

1.  Studies with bromocriptine. Part 1. "On-off" phenomena.

Authors:  R Kartznel; D B Calne
Journal:  Neurology       Date:  1976-06       Impact factor: 9.910

2.  The role of bromocriptine in the treatment of parkinsonism.

Authors:  S Fahn; L J Cote; S R Snider; R E Barrett; W P Isgreen
Journal:  Neurology       Date:  1979-08       Impact factor: 9.910

3.  Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.

Authors:  J D Parkes; A G Debono; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-11       Impact factor: 10.154

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Bromocriptine treatment in Parkinson's disease.

Authors:  J D Parkes; C D Marsden; I Donaldson; A Galea-Debono; J Walters; G Kennedy; P Asselman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-02       Impact factor: 10.154

6.  Bromocriptine in Parkinson disease: further studies.

Authors:  A N Lieberman; M Kupersmith; G Gopinathan; E Estey; A Goodgold; M Goldstein
Journal:  Neurology       Date:  1979-03       Impact factor: 9.910

7.  Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.

Authors:  R Kartzinel; P TEYCHENNE; M M Gillespie; M Perlow; A C Gielen; D A Sadowsky; D B Calne
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

8.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

9.  Long-term efficacy of bromocriptine in Parkinson disease.

Authors:  A Lieberman; M Kupersmith; A Neophytides; I Casson; R Durso; S H Foo; M Khayali; G Bear; M Goldstein
Journal:  Neurology       Date:  1980-05       Impact factor: 9.910

10.  Long-term treatment of parkinsonism with bromocriptine.

Authors:  D B Calne; C Plotkin; A C Williams; J G Nutt; A Neophytides; P F Teychenne
Journal:  Lancet       Date:  1978-04-08       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.